Literature DB >> 19198242

[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].

Kumi Uekita1, Takashi Ishida, Satoko Sekine, Taeko Ishii, Suguru Sato, Aya Sugawara, Motoko Tachihara, Kana Watanabe, Kenya Kanazawa, Junpei Saito, Yoshinori Tanino, Mitsuru Munakata.   

Abstract

A 77-year-old man was admitted to our hospital with muscle weakness and shortness of breath. Chest CT showed a mass in the left upper lobe, and electromyography showed waxing phenomenon with high-frequency repetitive stimulation. We diagnosed Lambert-Eaton myasthenic syndrome accompanying small cell lung cancer. He was treated with carboplatin and etoposide, and concurrent thoracic irradiation. Although, the tumor size decreased, his myasthenic symptoms remained. He started taking 3,4-diaminopyridine and his muscle weakness improved dramatically, and he was eventually able to walk finally. In some cases, anti-tumor therapies cannot improve the myasthenic symptoms. In such cases, 3,4-diaminopyridine could improve the quality of life, and should be approved in Japan.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19198242

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  2 in total

1.  Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report.

Authors:  Jae-Won Hyun; Su-Hyun Kim; In Hye Jeong; Heung Tae Kim; Ho Jin Kim
Journal:  Oncol Lett       Date:  2016-01-18       Impact factor: 2.967

2.  Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.

Authors:  Simona Portaro; Teresa Brizzi; Stefano Sinicropi; Alberto Cacciola; Maria Cristina De Cola; Alessia Bramanti; Demetrio Milardi; Antonino Lupica; Placido Bramanti; Antonio Toscano; Carmelo Rodolico
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.